Allakos Inc. (ALLK)
0.87
-0.01 (-1.32%)
At close: Jan 15, 2025, 11:52 AM
undefined% (undefined)
| Bid | 0.85 |
| Market Cap | 77.84M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.03 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.87 |
| Volume | 48,486 |
| Avg. Volume (20D) | 702,463 |
| Open | 0.86 |
| Previous Close | 0.88 |
| Day's Range | 0.86 - 0.89 |
| 52-Week Range | 0.54 - 1.69 |
| Beta | undefined |
About ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 19, 2018
Employees 131
Stock Exchange NASDAQ
Ticker Symbol ALLK
Website https://www.allakos.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 14.78% from the latest price.
Buy 25.00%
Hold 50.00%
Sell 25.00%
3 months ago ·
Source
+1.37%
Allakos shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago ·
Source
-9.9%
Allakos shares are trading higher after the company reported better-than-expected Q2 EPS results.
